Indian pharma major Lupin (BSE: 500257) saw its shares fall 3.75% to 833.15 rupees this morning despite announcing that it has received approval from the UK health regulator for its Goa manufacturing facility.
In a regulatory filing, Lupin said it “has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its Goa facility.
The unit was inspected by the MHRA in March 2018 and there were no critical or major observations cited, it added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze